Ovagen: Dosage, Evidence and Legal Status
Ovagen is sold as a Khavinson bioregulator, but I could not find a single published study of a peptide by this name.
The short version
Ovagen is sold as a short peptide from the Russian Khavinson bioregulator line, marketed for ovarian and reproductive-system support. I searched PubMed under every variant of its name and found no indexed study of a peptide called Ovagen: no clinical trial, no animal study, nothing. Vendor pages even disagree about which organ system it targets.
- I could not find one published study of a peptide called Ovagen, in any language, on PubMed.
- Vendor pages disagree with each other on basic facts, including what organ system it targets.
- The common oral protocol comes from clinic and vendor dosing pages; there is no research to draw a dose from.
- Not approved for human use anywhere; sold as a research chemical or unregulated supplement.
Ovagen at a glance
- What it is
- Short synthetic peptide sold as a Khavinson-line tissue bioregulator
- Main use
- Marketed for ovarian and reproductive-system support and healthy aging, within the Khavinson peptide-bioregulator line.
- Also called
- Ova bioregulator
- Molecular formula
- C15H25N3O8 (375.37 g/mol) Structure
- Evidence
- No meaningful evidence
- US status
- Research use only
- Half-life
- Not established in humans
- How it is taken
- By mouth
- Common protocol
- 10-20 mg, 1-2 capsules (10 mg each), taken once or twice daily before meals, for 1.4-2.9 weeks (common practice, not trial-established)
Ovagen is sold as a Khavinson-line peptide bioregulator, from the same Russian research tradition as Epitalon and Pinealon Khavinson 2002 - Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144., in the references below. I searched for published research under this name and found none. That absence is the most important fact on this page.
What is Ovagen?
Ovagen is marketed as a short peptide to support ovarian and reproductive-system function, alongside the general healthy-aging claims made for the whole Khavinson line. The idea behind that line is that a short peptide from a given tissue helps regulate gene activity in the organ it is named for.
Some sibling compounds have real, published lab support for that idea in specific ageing tissue models. For Ovagen, I couldn’t verify it at all, as the research section explains.
Ovagen structure
- Molecular formula
- C15H25N3O8
- Molecular weight
- 375.37 g/mol
- Length
- 3 amino acids
- Sequence
- EDL
- Modifications
- Glu-Asp-Leu; free N- and C-termini; all L-amino acids.
- PubChem CID
- 444128
The developers' own 2022 review identifies Ovagen as the tripeptide Glu-Asp-Leu but lists its reported activity as liver- and kidney-protective, not ovarian; the product name does not match that description.
Identity checked against Khavinson et al., Int J Mol Sci 2022 (developers' review of their short peptides).
Ovagen benefits: what the research shows
There is no research to show. A PubMed search for “Ovagen” returns results, but the first 20 are all unrelated papers, on wastewater-treatment analytics, geriatric palliative care and cattle superovulation. They match only because of how the search engine expands the term.
Combining “Khavinson” with “ovary” or “ovarian peptide” returns a few results, and none are about Ovagen either. PubMed doesn’t even index “Ovagen” as a recognised concept, as it does for some siblings, such as the tetrapeptide behind Pancragen.
I cover compounds people are actually buying, and Ovagen is one. That is why I don’t write mechanism or benefit claims here that no source supports. For a sibling compound with at least some real lab data, see Pinealon or Livagen.
Ovagen dosage
No published study, of any kind or in any species, exists to draw a dose from. Clinic and vendor dosing pages commonly describe 10-20 mg by mouth (1-2 capsules of 10 mg), once or twice daily before meals, for a 10-20 day course with a 2-6 month break before repeating. That is common practice, not a number any trial or regulator has set.
Common protocol
What is commonly used, not a dose established in trials. No regulator has set a dose for Ovagen. Sources differ, so the ranges below span them.
- Dose
- 10-20 mg
- How often
- 1-2 capsules (10 mg each), taken once or twice daily before meals
- Route
- By mouth
- Cycle length
- 1.4-2.9 weeks
- Break between cycles
- 9-26 weeks
- Timing
- By mouth, 15-30 minutes before a meal.
Sources disagree on exact dosing frequency (twice daily versus a daily total not split by dose) and on how long the break between courses runs (2-4 months versus 3-6 months), so both are kept as ranges. Neither source states what organ system Ovagen is meant to act on with any consistency, which matches the compound guide's finding that no published study under this name exists to settle it.
Ovagen side effects
There is no human or animal safety data for Ovagen, because no published study of it exists. Any effects users report are anecdotal, with no controlled study behind them.
Is Ovagen legal?
US legal status - Research use only
Sold for laboratory research use only. Not approved by the FDA for human use, and cannot be lawfully marketed as a supplement or a medicine. Products sold this way are not made to pharmaceutical quality standards, and their contents are not verified by anyone.
Ovagen is not approved for human use anywhere. It is sold as a research chemical or unregulated supplement, and no regulator checks that what you receive matches its label.
Regulatory changes for this compound and others, as they happen: US peptide regulation tracker.
Related
How Ovagen compares
Bioregulators. Doses for unapproved compounds are common practice, not trial-established. All bioregulators peptides →
| Compound | Main use | Evidence | Usual dose | US status |
|---|---|---|---|---|
| Ovagen | Marketed for ovarian and reproductive-system support and healthy aging, within the Khavinson peptide-bioregulator line. | No meaningful evidence | 10-20 mg, 1-2 capsules (10 mg each), taken once or twice daily before meals | Research use only |
| Epitalon | Sold for longevity and anti-aging on the basis of telomere research. | Animal / lab only | 5-10 mg, once nightly, every night, for the length of the cycle | Research use only |
| Pinealon | Sold for cognition, focus and healthy aging. | Limited human data | 1-2 mg, once daily, morning preferred; some protocols run 5 days a week rather than every day | Research use only |
| Cartalax | Marketed for cartilage and joint support, sold as a "cartilage bioregulator" for age-related joint wear. | Animal / lab only | 200 mcg, once daily | Research use only |
| Testagen | Marketed for testosterone and reproductive-system support, sold as a "testes bioregulator." | Animal / lab only | 10-20 mg, once daily by mouth | Research use only |
| Vilon | Marketed as a thymus and immune-system bioregulator, sold for immune support and healthy ageing. | Animal / lab only | 10-20 mg, once daily by mouth | Research use only |
| Vesugen | Marketed as a vascular-tissue bioregulator for cardiovascular and blood-vessel aging; more recent papers from the same research group also study it as a candidate for age-related cognitive decline. | Limited human data | 500-5000 mcg, once daily, subcutaneous, commonly started low and titrated upward over the first 1-3 weeks | Research use only |
| Cardiogen | Marketed as a heart-tissue bioregulator for cardiovascular aging, from the Khavinson organ-specific peptide programme. | Animal / lab only | 200-2000 mcg, once daily, subcutaneous, most commonly cited around 1 mg/day | Research use only |
Where to buy Ovagen for research
Each vendor is checked against my vendor checklist.
1.BioEdge Research Labs
20 mg vial
- No FDA warning letter found
- Names its testing lab
- Batch COAs published
Common questions
Is there any published research on Ovagen?
I couldn't find any. A PubMed search for "Ovagen" returns results, but the first 20 are all unrelated papers matched by how the search expands the term: wastewater treatment, geriatric care, cattle superovulation. Combining "Khavinson" with "ovary" or "ovarian peptide" finds a few unrelated hits too. Unlike some sibling bioregulators, PubMed doesn't even recognise "Ovagen" as a concept.
What is the usual Ovagen dose?
No published study sets one, because no published study of this peptide exists. Clinic and vendor pages commonly describe 10-20 mg by mouth, once or twice daily before meals, for a 10-20 day course with a 2-6 month break. That is common practice, not trial-based; see the dosing section below.
What are the side effects of Ovagen?
There is no published safety data of any kind, human or animal, so there is no established side-effect rate. Any effects users report are anecdotal, not clinical findings.
References (1 sources)
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.
- 1.Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144.ReviewPMID 12374906